PARP1 and ovarian carcinoma: If confirmed, [18F]PARP1‐inhibitor PET may serve as a biomarker to identify low‐grade ovarian cancer patients with unexpectedly high PARP1 expression, indicating potential sensitivity to PARP inhibitors, even if they do not have breast cancer gene (BRCA) mutations or homologous recombination deficiency.